Elevated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement

Endocrine Journal

Volumn 54, Issue 1, 2007, Pages 45-52

  Akinci, Baris ^a   Comlekci, Abdurrahman ^a   Ali Ozcan, Mehmet ^a   Demir, Tevfik ^a   Yener, Serkan ^a   Demirkan, Fatih ^a   Yuksel, Faize ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Fibrinolysis; Hypothyroidism; Levothyroxine; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ANTIGEN; LEVOTHYROXINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHYROIDISM; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; THROMBOSIS;

ADULT; AGED; ANTIGENS; CARBOXYPEPTIDASE U; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; RESEARCH DESIGN; THYROXINE;

EID: 33947601821     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-062     Document Type: Article

References (37)

1. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43: 55-68.
2. Cappola AR, Ladenson PW (2003) Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 88: 2438-2444.
3. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 132: 270-278.
4. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342: 1076-1079.
5. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96: 1102-1108.
6. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J (1994) Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 14: 54-59.
7. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I (1998) Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 80: 749-756.
8. Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270: 14477-14484.
9. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME (1998) A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273: 27176-27181.
10. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P (2003) Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost 89: 554-560.
11. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP (2002) Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88: 1020-1025.
12. Hofbauer LC, Heufelder AE (1997) Coagulation disorders in thyroid diseases. Eur J Endocrinol 136: 1-7.
13. Ford HC, Carter JM (1990) Haemostasis in hypothyroidism. Postgrad Med J 66: 280-284.
14. Muller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ, Marbet GA (2001) Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 31: 131-137.
15. Erem C, Kavgaci H, Ersoz HO, Hacihasanoglu A, Ukinc K, Karti SS, Deger O, Telatari M (2003) Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 57: 78-81.
16. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M, Duman C (2003) Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 13: 971-977.
17. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271: 16603-16608.
18. Bajzar L, Jain N, Wang P, Walker JB (2004) Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 32 (Suppl 5): S320-324.
19. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F (2005) TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 3: 1503-1510.
20. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22: 867-873.
21. Juhan-Vague I, Morange PE (2003) Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. J Thromb Haemost 1: 2243-2244.
22. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84: 364-368.
23. Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH (2003) Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost 90: 1187-1191.
24. Malyszko J, Malyszko JS, Hryszko T, Brzosko S, Lebkowska U, Mysliwiec M (2005) Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries. Transpl Int 18: 256-259.
25. Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J (2004) Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89: 880-881.
26. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34: 1038-1040.
27. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J (2003) Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34: 2387-2391.
28. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3: 2211-2218.
29. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ (1993) Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 68: 860-866.
30. Bruni F, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Cercigani M, Leo A, Auteri A, Puccetti L (2004) Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol 95: 269-274.
31. Malyszko J, Malyszko JS, Mysliwiec M (2003) Fluvastin therapy affects TAFI concentration in kidney transplant recipients. Transpl Int 16: 53-57.
32. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T (2005) Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 28: 2211-2216.
33. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G (2001) Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 86: 732-737.
34. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M (2004) Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb Haemost 91: 480-486.
35. Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Mysliwiec M (2001) Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor. Thromb Res 104: 233-238.
36. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y (2002) Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 87: 660-665.
37. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Salvetti A, Ferrannini E, Monzani F (2003) Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88: 3731-3737.